Skip to main content
. Author manuscript; available in PMC: 2014 May 14.
Published in final edited form as: J Thorac Oncol. 2010 Oct;5(10):1623–1629. doi: 10.1097/JTO.0b013e3181ec1531

FIGURE 2.

FIGURE 2

Maximal percentage of tumor reduction for target lesions by RECIST in patients receiving everolimus and gefitinib who had been previously treated with chemotherapy. Bars without mutations represent patients whose tumors are wild type for epidermal growth factor receptor (EGFR) and KRAS.